Continuous measurement of radioactivity for a patient with chronic kidney disease during radioactive iodine therapy and hemodialysis: a case report.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2025-04-09 eCollection Date: 2025-07-01 DOI:10.1007/s13691-025-00756-z

Takuma Usuzaki, Hiroyasu Kodama, Mariko Miyazaki, Keiichi Jingu

{"title":"Continuous measurement of radioactivity for a patient with chronic kidney disease during radioactive iodine therapy and hemodialysis: a case report.","authors":"Takuma Usuzaki, Hiroyasu Kodama, Mariko Miyazaki, Keiichi Jingu","doi":"10.1007/s13691-025-00756-z","DOIUrl":null,"url":null,"abstract":"The half-life of radioactive iodine (RAI) is prolonged in patients with chronic kidney disease (CKD) because RAI is mainly excreted by the kidneys. There is little information on the RAI half-life in patients with dialysis-dependent CKD (CKDG5d). Estimating the RAI half-life in a patient's body provides important information for treatment planning. In this paper, we report a 68-year-old woman of CKDG5d who underwent postsurgical RAI therapy for papillary adenocarcinoma of the thyroid. We administered 15 mCi (0.56 GBq) RAI (131I) and continuously measured the dose equivalent rate. The results were summarized into hourly values of dose equivalent rate. Based on the measurements, we estimated the RAI half-life in the patient's body using a semi-log plot and linear regression analysis. In addition, we calculated the integrated doses for caregivers and the public using coefficients of 0.5 and 0.25, respectively. The half-life in the patient's body was 7.2 days (95% confidence interval, 4.8-14.4). The integrated doses for caregivers and the public were 0.23 mSv and 0.11 mSv, respectively. RAI therapy for a CKDG5d patient should be planned on the basis of the biological dynamics of 131I. Accumulation of more cases should lead to the establishment of a treatment strategy for patients undergoing RAI therapy and hemodialysis.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"220-228"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229431/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-025-00756-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The half-life of radioactive iodine (RAI) is prolonged in patients with chronic kidney disease (CKD) because RAI is mainly excreted by the kidneys. There is little information on the RAI half-life in patients with dialysis-dependent CKD (CKDG5d). Estimating the RAI half-life in a patient's body provides important information for treatment planning. In this paper, we report a 68-year-old woman of CKDG5d who underwent postsurgical RAI therapy for papillary adenocarcinoma of the thyroid. We administered 15 mCi (0.56 GBq) RAI (¹³¹I) and continuously measured the dose equivalent rate. The results were summarized into hourly values of dose equivalent rate. Based on the measurements, we estimated the RAI half-life in the patient's body using a semi-log plot and linear regression analysis. In addition, we calculated the integrated doses for caregivers and the public using coefficients of 0.5 and 0.25, respectively. The half-life in the patient's body was 7.2 days (95% confidence interval, 4.8-14.4). The integrated doses for caregivers and the public were 0.23 mSv and 0.11 mSv, respectively. RAI therapy for a CKDG5d patient should be planned on the basis of the biological dynamics of ¹³¹I. Accumulation of more cases should lead to the establishment of a treatment strategy for patients undergoing RAI therapy and hemodialysis.

查看原文本刊更多论文

放射性碘治疗和血液透析期间慢性肾病患者放射性的连续测量：1例报告。

慢性肾脏疾病（CKD）患者放射性碘（RAI）的半衰期延长，因为RAI主要由肾脏排出。关于透析依赖性CKD （CKDG5d）患者RAI半衰期的信息很少。估计RAI在患者体内的半衰期为制定治疗计划提供了重要信息。在本文中，我们报告了一位68岁的CKDG5d女性，她因甲状腺乳头状腺癌接受了术后RAI治疗。我们给药15 mCi (0.56 GBq) RAI (131I)，并连续测量剂量当量率。结果汇总成剂量当量率的小时值。根据测量结果，我们使用半对数图和线性回归分析估计RAI在患者体内的半衰期。此外，我们分别使用0.5和0.25的系数计算了护理人员和公众的综合剂量。在患者体内的半衰期为7.2天（95%可信区间为4.8-14.4）。护理人员和公众的综合剂量分别为0.23毫西弗和0.11毫西弗。CKDG5d患者的RAI治疗应根据131I的生物学动力学来规划。更多病例的积累应该导致对接受RAI治疗和血液透析的患者建立治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)